---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-23-008159"
form_type: "8-K"
ticker: "CNSP"
cik: "0001729427"
company_name: "CNS Pharmaceuticals, Inc."
filed_at: "2023-11-15T23:59:59+00:00"
generated_at: "2026-06-08T02:35:54.691216+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CNS Pharma Q3 net loss $4.5M; Berubicin enrollment at 239, interim data Dec 2023

## Summary
- Net loss of $4.5M vs $3.4M in Q3 2022; R&D expenses rose to $3.4M on clinical progress.
- Cash at Sept 30 was $0.9M; raised $2.6M in October via warrant/ATM; expects to fund operations through Q4 2023.
- Enrollment in potentially pivotal Berubicin GBM study reached 239 patients; full enrollment expected Dec 2023.
- Topline data from interim analysis expected in December 2023; 45 of 60 trial sites activated across US and Europe.

## SEC filing metadata
- accession: 0001683168-23-008159
- form_type: 8-K
- ticker: CNSP
- cik: 0001729427
- company_name: CNS Pharmaceuticals, Inc.
- filed_at: 2023-11-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1729427/000168316823008159/0001683168-23-008159-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1729427/000168316823008159/cns_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-23-008159
- JSON: https://secwatch.observer/filing/0001683168-23-008159.json
- Plain text: https://secwatch.observer/filing/0001683168-23-008159.txt

## Key facts
- Earnings Releases
  CNS Pharmaceuticals, Inc. reported financial results for the quarter ended September 30, 2023.
  - Period: the quarter ended September 30, 2023
  - Result: reported results
  source text: On November 15, 2023, CNS Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the period ended September 30, 2023 and recent operational highlights.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1729427/000168316823008159/0001683168-23-008159-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.